Intelligence Feed event · Policy · 2026-09-28

    HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 in Solid Tumors

    Question

    HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 in Solid Tumors

    Direct answer

    HUTCHMED announced the dosing of the first patient on September 24, 2026, in its global Phase Ia clinical study evaluating HMPL-A830. The molecule represents a novel antibody-targeted therapy conjugate combining a KRAS inhibitor with an anti-EGFR antibody targeting refractory solid tumors. The asset is being advanced under an exclusive global development and commercialization partnership with GSK, marking progress in dual-targeting oncogenic signaling pathways.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-28
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 in Solid Tumors”, revision 1, evidence through 2026-09-28. https://marketontology.com/market-events/2026-09-28/hutchmed-doses-first-patient-in-global-phase-ia-trial-of-hmpl-a830-in-solid-tumo-f01e4b

    POLICY
    HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 in Solid Tumors
    HUTCHMED announced the dosing of the first patient on September 24, 2026, in its global Phase Ia clinical study evaluating HMPL-A830. The molecule represents a novel antibody-targeted therapy conjugate combining a KRAS inhibitor with an anti-EGFR antibody targeting refractory solid tumors. The asset is being advanced under an exclusive global development and commercialization partnership with GSK, marking progress in dual-targeting oncogenic signaling pathways.
    HCMGSK
    Impact
    65
    SEP 28
    SIG
    90%
    HCMGSK
    HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 in Solid Tumors
    HUTCHMED announced the dosing of the first patient on September 24, 2026, in its global Phase Ia clinical study evaluating HMPL-A830. The molecule represents a novel antibody-targeted therapy conjugate combining a KRAS inhibitor with an anti-EGFR antibody targeting refractory solid tumors. The asset is being advanced under an exclusive global development and commercialization partnership with GSK, marking progress in dual-targeting oncogenic signaling pathways.
    → First patient dosing in Phase Ia triggers clinical development milestone progress for HUTCHMED and its partner GSK in targeted oncology.
    Impact
    HUTCHMED announced the dosing of the first patient on September 24, 2026, in its global Phase Ia clinical study evaluating HMPL-A830. The molecule represents a novel antibody-targeted therapy conjugate combining a KRAS inhibitor with an anti-EGFR antibody targeting refractory solid tumors. The asset is being advanced under an exclusive global development and commercialization partnership with GSK, marking progress in dual-targeting oncogenic signaling pathways.
    Affected
    HCMGSK
    Transmission
    First patient dosing in Phase Ia triggers clinical development milestone progress for HUTCHMED and its partner GSK in targeted oncology.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    HCMclinical milestone progression in partnered oncology pipelineUp1-3mFirst patient dosed on September 24, 2026, in Phase Ia study of HMPL-A830.
    GSKpartnered pipeline expansion in KRAS-EGFR targeted oncology conjugatesUp1-3mGSK holds exclusive development and partnership agreement with HUTCHMED.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    HCMUpagreed14.13 2026-09-28+0.14%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month